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all patients in the study. For tumours from Vietnamese patients,
hormone-receptor status was analysed by immunohistochemis-
try, using an automated slide stainer (Bench MarkXT, Ventana)
in combination with anti-ER (SP1 250) and anti-PgR (clone 1E2)
rabbit monoclonal antibodies. Tumours with 10% or more stained
nuclei were considered receptor positive. Tumours from Swedish
patients were analysed with an enzyme immunoassay, with a
cut-off point of 0.10 fmol/lg DNA as positive. The hormone-
receptor frequencies between populations were compared
according to clinicopathologic features.
Findings: Compared with Swedish patients with similar meno-
pausal status, the ER-positive rate was higher in premenopausal
Vietnamese patients (71% vs. 58%, p = 0.007) and lower in post-
menopausal Vietnamese patients (45% vs. 72%, p < 0.001). PgR-
positive tumours were found in 58% of premenopausal and 25%
of postmenopausal Vietnamese patients. The corresponding fig-
ures for Swedish patients were 73% and 66%, respectively.
Interpretation: ER positivity in Vietnamese patients decreased
gradually with rising patient age, by contrast with the trend
observed for Swedish patients, who showed a gradual increase
with age. PgR positivity was lower for Vietnamese than for Swed-
ish patients, regardless of age or menopausal status. Our findings
suggest that a high percentage of young patients could benefit
from endocrine therapy, and indicate a limited benefit among
postmenopausal Vietnamese patients.
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Background: SPARC-like protein 1 (SPARCL1) is an extracelluar
matrix glycoprotein involved in many physiological functions.
Studies have shown an important role for SPARCL1 in cancer
development and progression.
Methods: Tissue microarray blocks were constructed based on
1072 Chinese patients, containing gastric-cancer tissue and adja-
cent normal-mucosa tissue. We analysed expression of SPARCL1
from mRNA and at the protein level, using real-time quantitative
polymerase chain reaction (qRT-PCR), semi-quantitative PCR,
immunohistochemistry (IHC), and Western blotting. We analysed
loss of heterozygosity at the SPARCL1 gene locus, using ten
tumour and matched normal-tissue pairs.
Findings: SPARCL1 mRNA was substantially lower in tumour
specimens than in normal tissues. Down-regulation of SPARCL1
protein was detected in 413 (38.7%) of 1072 primary gastric-
tumour tissues. Significant differences in expression were found
according to histological type, tumour size, depth of invasion,
regional lymph-node involvement, TNM stage, and differentia-
tion. Low expression of SPARCL1 was more common in poorly dif-
ferentiated and undifferentiated tumour tissues (51.1%) than in
well and moderately differentiated tumours (29.9%). Kaplan–
Meier survival curves showed that SPARCL1-positive patients
had longer median survival than SPARCL1-negative patients (59
months vs. 28 months, p = 0.001). Our data also showed signifi-
cantly lower 5-year survival for patients with reduced expression
of SPARCL1 (37.8%) than for patients with high expression (49.7%;
p < 0.001). The incidence of loss of heterozygosity for each indi-
vidual marker was 12.5% (1 of 8) for D4S2462, 20% (2 of 10) for
D4S2929 and 33.3% (3 of 9) for SPARCL1.
Interpretation: Our study revealed the clinical significance of
SPARCL1 expression, providing a basis for a novel negative bio-
marker in gastric-cancer progression and prognosis. Further-
more, SPARCL1 protein might be considered a potential
differentiation marker.
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Background: We did a multi-institutional propensity-matched
study comparing video-assisted thoracic surgery (VATS) with
1 These authors contributed equally.
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conventional open lobectomy for patients with non-small-cell
lung cancer (NSCLC), to stratify potential differences in long-term
survival outcomes.
Methods: We established a multi-institutional registry for 4138
patients with NSCLC who underwent lobectomy between January,
2000, and December, 2007, from eight institutions in China. Age,
gender, histological type, and tumour staging, based on the latest
TNM classification, were entered into a non-parsimonious multi-
variable logistic-regression model. The predicted probability
derived from the logistic equation was used as the propensity
score for each individual. Based on similar propensity scores,
we matched 1356 of the 1584 patients who underwent VATS
lobectomy with 1356 of the 2554 patients who underwent open
lobectomy, and compared their long-term survival outcomes.
Findings: The mean age of the 2712 matched patients was 59
years (SD 11). After propensity matching, VATS and open lobec-
tomy were similar with regard to important prognostic variables.
In multivariate analysis, four prognostic factors were indepen-
dently associated with improved survival: gender (p = 0.001), his-
tological type (p < 0.001), pathological staging (p < 0.001), and
surgery type (lobectomy/sleeve resection vs. pneumonectomy
(p = 0.044). Patients who underwent VATS versus open lobectomy
had similar long-term survival (p = 0.101).
Interpretation: The current propensity-score analysis suggests
that well-matched patients with NSCLC who underwent VATS
lobectomy did not have inferior long-term survival outcomes
compared with those who underwent open lobectomy.
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Background: We investigated the significance of CD24 and CD44
expression for predicting response to chemotherapy, and progno-
sis, in patients with primary breast cancer.
Methods: Diagnosis of breast cancer was confirmed by core-
needle biopsy, and immunohistochemical studies were
performed. Preoperatively, patients received anthracycline-con-
taining chemotherapy. Expression of CD44 and CD24 was
assessed immunohistochemically and the association with che-
motherapy response and prognosis was analysed.
Findings: 139 women were enrolled in this study between 2001
and 2004. In correlation analysis, CD24 expression was negatively
associated with pathological response to chemotherapy
(p = 0.0003). A machine learning technique with an alternating
decision tree showed that four logical rules are involved in pre-
dicting response, depending on the combination of CD24, HER2,
tumour stage, CD44, progesterone receptor, and patient age. In
survival analysis, patients who were CD44 (++) showed a signifi-
cantly favourable prognosis compared with others (p = 0.0002).
Multivariate analysis showed that CD44 expression had an inde-
pendent prognostic value (p < 0.001).
Interpretation: We found a significant correlation between CD44
expression and prognosis, and between CD24 expression and
response to chemotherapy. CD24 and CD44 expression could be
useful predictive markers, although further studies are needed.
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Introduction: The American Cancer Society estimated 70,980
new cases of bladder cancer in the USA during 2009, with
approximately 14,330 bladder-cancer-related deaths during the
same period. Cystoscopy, the gold standard diagnostic evaluation
for detection of bladder cancer and surveillance after therapy, is
invasive, expensive, and unpopular among patients. Urine
cytology, as an adjunct to cystoscopy, is less sensitive for low-
grade tumours. This study evaluated the clinical significance of
survivin (an inhibitor of apoptosis) mRNA expression in diagnosis
of transitional-cell carcinoma (TCC) in patients with bladder
cancer.
Methods: Quantitative detection of survivin mRNA expression
was evaluated in exfoliated cells in urine, by use of real-time
quantitative (qRT)-PCR, in 135 patients with suspicion of new or
recurrent bladder cancer, prior to transurethral resection. Of 135
cases, 98 were histologically proven TCC, whereas 37 had other,
benign urological diseases. Fifteen healthy volunteers were also
included, as well as 62 patients with treated superficial bladder
cancer who had a current negative biopsy and were receiving fol-
low-up care.
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